Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Autolus Therapeutics Plc ADR
(NQ:
AUTL
)
2.840
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Autolus Therapeutics Plc ADR
< Previous
1
2
3
4
5
6
Next >
Autolus Therapeutics Announces Changes to its Board of Directors
April 01, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 20, 2024
Via
Benzinga
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
March 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
March 15, 2024
Via
Benzinga
Autolus Therapeutics's Earnings Outlook
March 13, 2024
Via
Benzinga
Analyst Expectations for Autolus Therapeutics's Future
December 13, 2023
Via
Benzinga
Autolus Therapeutics PLC (NASDAQ: AUTL) Climbs to New 52-Week High
November 20, 2023
Via
Investor Brand Network
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
March 14, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Earnings Scheduled For March 14, 2024
March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
Via
Benzinga
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
March 12, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces publication in Blood Cancer Journal
March 11, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
February 29, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces publication in Nature Communications
February 22, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Announces Pricing of Underwritten Offering
February 08, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces publication in ACS Chemical Biology
January 23, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
January 22, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Chart Of The Day: Autolus Therapeutics - Effective Cancer Treatments
January 12, 2024
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer.
Via
Talk Markets
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
January 10, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 27, 2023
Via
Benzinga
Autolus Therapeutics Announces Changes to its Board of Directors
December 22, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
December 09, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 28, 2023
Via
Benzinga
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
November 27, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 15, 2023
Via
Benzinga
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
November 15, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces participation in upcoming conferences
November 06, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations
November 02, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
November 02, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
October 17, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
October 11, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
